An Exploratory Clinical Study of TILs in the Treatment of Recurrent / Refractory Non-small Cell Lung Cancer (NSCLC)

NCT04919616 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

UNKNOWN

Status

15

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG: TILs（Tumor Infiltrating Lymphocytes）

Sponsor

Shanghai OriginCell Therapeutics Co., Ltd.